Trial record 1 of 1 for:
pretar | France
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03223961 |
|
Recruitment Status :
Recruiting
First Posted : July 21, 2017
Last Update Posted : December 2, 2020
|
Sponsor:
Groupe Francophone des Myelodysplasies
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an open-label, randomized, multicenter, phase III study
Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks:
- Either at diagnosis Or
- at the Hb threshold chosen for RBC transfusions (must be < 9g/dl)
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Myelodysplastic Syndromes | Drug: EPREX | Phase 3 |
in this trial we will compare the early introduction of EPO alfa to the delayed introduction in lower risk MDS with non RBC transfusion dependent anemia.
At enrollment patients will be randomised in the 2 arms (early and delayed start of EPO alfa).
Treatment Regimen Epoetin alfa 60000 UI/week for at least 12 weeks
- Early onset arm: early onset of EPO ALFA 60000 IU/week , at patient inclusion
- Delayed onset arm: late introduction of EPO ALFA 60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 124 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | randomazed study |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q |
| Actual Study Start Date : | March 26, 2018 |
| Estimated Primary Completion Date : | May 16, 2022 |
| Estimated Study Completion Date : | May 16, 2024 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Epoetin Alfa
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Early onset arm
Intervention: early onset of Eprex60000 IU/week , at patient inclusion
|
Drug: EPREX
60 000 U/week for at least 12 weeks
Other Name: Epoetin alfa |
|
Experimental: Delayed onset arm
Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
|
Drug: EPREX
60 000 U/week for at least 12 weeks
Other Name: Epoetin alfa |
Primary Outcome Measures :
- Time to RBC transfusion dependence in non RBC transfusion dependent lower risk MDS patients with anemia with early (at inclusion of the patient) versus delayed onset,( at the threshold chosen for RBC transfusion) of EPO ALFA [ Time Frame: 12 weeks ]RBC transfusion dependence will be defined by requirement of at least transfusions of 2 PRBC within an interval of less than 8 weeks, given for Hb <8g/dl or <9g/dl according to comorbidities and in the absence of other cause of anemia (bleeding, surgery…), taking into account only transfusions given at least 12 weeks after onset of treatment with EPO ALFA.
Secondary Outcome Measures :
- Erythroid response (according to IWG 2006 criteria) [ Time Frame: 12 weeks ]Erythroid response (according to IWG 2006 criteria) after 12 weeks of EPO ALFA treatment
- response duration to EPO ALFA [ Time Frame: 4 years ]response duration to EPO ALFA measured from the date of enrollment until failure
- Overall survival [ Time Frame: 4 years ]Overall survival measured from the date of enrollment to death or the date of last contact
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥ 18 years
- MDS according to WHO 2016 criteria, with low or int 1 classical IPSS
- Non-RBC transfusion dependent anemia
- Hb level between 9 and 10.5g/dl (at the center's lab)
- Hb level should be at least 1g/dl higher than the Hb threshold chosen to start RBC transfusions based on age, comorbidities and predicted clinical tolerance of anemia (this transfusion threshold should be chosen between 8 and 9g/dl)
- Serum EPO level <500U/l
- No other cause of anemia (including iron deficiency, vitamin B12 or B9 deficiency, hemolysis, hypothyroidism….)
- Performance status <=2
Exclusion Criteria:
- Higher risk MDS (IPSS intermediate-2 or high)
- Del 5q
- Baseline Hemoglobin level > 10.5 g/dl or <9g/dl
- Transfusion threshold (based on age , comorbidities…) >9g/dl
- Transfusion threshold less than 1 g/dl below baseline Hb level
- RBC transfusion dependence. Patients may have received only one transfusion series for MDS prior to inclusion
- CMML , if >10 % BM blasts or WBC>13.000/mm3
- Uncontrolled hypertension
- Uncontrolled cardiovascular disease including angina pectoris or cardiac failure
- Renal failure: Creatinine clearance<40ml/min (using MDRD formula)
- Pregnancy (positive bettaHCG) or nursing
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03223961
Contacts
| Contact: Sophie Park, Prof | +33 (0)4 76 76 62 77 | spark@chu-grenoble.fr | |
| Contact: Fatiha Chermat, CRA | +33 (0)1 71 20 70 59 | fatiha.chermat-ext@aphp.fr |
Locations
Show 39 study locations
Sponsors and Collaborators
Groupe Francophone des Myelodysplasies
Investigators
| Principal Investigator: | Sophie Park, Prof | University Hospital, Grenoble |
| Responsible Party: | Groupe Francophone des Myelodysplasies |
| ClinicalTrials.gov Identifier: | NCT03223961 |
| Other Study ID Numbers: |
GFM-EPO-PRETAR |
| First Posted: | July 21, 2017 Key Record Dates |
| Last Update Posted: | December 2, 2020 |
| Last Verified: | November 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Groupe Francophone des Myelodysplasies:
|
myelodysplastic syndrome erythropoetin |
Additional relevant MeSH terms:
|
Preleukemia Myelodysplastic Syndromes Bone Marrow Diseases Hematologic Diseases |
Precancerous Conditions Neoplasms Epoetin Alfa Hematinics |